Localized insulin-like growth factor I delivery to enhance new bone formation

Bone

Volumn 33, Issue 4, 2003, Pages 660-672

  Meinel, Lorenz ^a   Zoidis, Evangelos ^b   Zapf, Jürgen ^b   Hassa, Paulo ^c   Hottiger, Michael O ^c   Auer, Jörg A ^c   Schneider, Rebecca ^c   Gander, Bruno ^a   Luginbuehl, Vera ^a   Bettschart Wolfisberger, Regula ^c   Illi, Oscar E ^c   Merkle, Hans P ^a   Von Rechenberg, Brigitte ^c  

^a ETH ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Biodegradable drug delivery microspheres; Fracture healing; Inflammation; Insulin like growth factor I; Messenger RNA; Protein delivery

Indexed keywords

BIOCHEMICAL MARKER; CYCLOOXYGENASE 2; GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MICROSPHERE; NITRIC OXIDE SYNTHASE; PLATELET DERIVED GROWTH FACTOR A; POLYGLACTIN; PROTEIN; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIODEGRADATION; BONE; BONE DEFECT; BONE INJURY; BONE REGENERATION; CANCELLOUS BONE; CONTROLLED STUDY; DOWN REGULATION; DRILL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFECT; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MEASUREMENT; MEDIATOR; METAPHYSIS; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOLYSIS; POLYMERASE CHAIN REACTION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; TIBIA;

EID: 12444321550     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(03)00207-2     Document Type: Article

References (43)

1. Service R.F. Tissue engineers build new bone [news]. Science. 289:2000;1498-1500.
2. Hunziker E.B., Wagner J., Zapf J. Differential effects of insulin-like growth factor I and growth hormone on developmental stages of rat growth plate chondrocytes in vivo. J Clin Invest. 93:1994;1078-1086.
3. Hyun D.K., Valentini R.F. Protein therapeutics for skeletal tissue repair. Mathiowitz E. Encyclopedia of controlled drug delivery 2. 1999;889-895 Wiley, New York.
4. Kirker-Head C.A. Potential applications and delivery strategies for bone morphogenetic proteins. Adv Drug Deliv Rev. 43:2000;65-92.
5. Nicolas V., Prewett A., Bettica P., Mohan S., Finkelman R.D., Baylink D.J., Farley J.R. Age-related decreases in insulin-like growth factor-I and transforming growth factor-beta in femoral cortical bone from both men and women implications for bone loss with aging . J Clin Endocrinol Metab. 78:1994;1011-1016.
6. Bostrom M, Lane JM, Tornin E, Browne M, Berberian W, Turek T, Smith J, Wozney J, Schildhauer T. Use of bone morphogenetic protein-2 in the rabbit ulnar nonunion model. Clin Orthop 1996;272-82.
7. Einhorn T.A., Lee C.A. Bone regeneration new findings and potential clinical applications . J Am Acad Orthop Surg. 9:2001;157-165.
8. Gerhart TN, Kirker-Head CA, Kriz MJ, Holtrop ME, Hennig GE, Hipp J, Schelling SH, Wang E. Healing segmental femoral defects in sheep using recombinant human bone morphogenetic protein. Clin Orthop 1993;317-26.
9. Lind M. Growth factors possible new clinical tools. A review . Acta Orthop Scand. 67:1996;407-417.
10. Ernst M., Froesch E.R. Growth hormone dependent stimulation of osteoblast-like cells in serum-free cultures via local synthesis of insulin-like growth factor I. Biochem Biophys Res Commun. 151:1988;142-147.
11. Lind M., Deleuran B., Thestrup-Pedersen K., Soballe K., Eriksen E.F., Bunger C. Chemotaxis of human osteoblasts. Effects of osteotropic growth factors. Apmis. 103:1995;140-146.
12. Panagakos F.S. Insulin-like growth factors-I and -II stimulate chemotaxis of osteoblasts isolated from fetal rat calvaria. Biochimie. 75:1993;991-994.
13. Schmid C., Steiner T., Froesch E.R. Insulin-like growth factor I supports differentiation of cultured osteoblast-like cells. FEBS Lett. 173:1984;48-52.
14. Balaram S.K., Agrawal D.K., Edwards J.D. Insulin like growth factor-1 activates nuclear factor-kappaB and increases transcription of the intercellular adhesion molecule-1 gene in endothelial cells. Cardiovasc Surg. 7:1999;91-97.
15. Heck S., Lezoualc'h F., Engert S., Behl C. Insulin-like growth factor-1-mediated neuroprotection against oxidative stress is associated with activation of nuclear factor kappaB. J Biol Chem. 274:1999;9828-9835.
16. Aspenberg P., Albrektsson T., Thorngren K.G. Local application of growth-factor IGF-1 to healing bone. Experiments with a titanium chamber in rabbits. Acta Orthop Scand. 60:1989;607-610.
17. Kirkeby O.J., Ekeland A. No effect of systemic administration of somatomedin C on bone repair in rats. Acta Orthop Scand. 61:1990;335-338.
18. Kirkeby O.J., Ekeland A. No effects of local somatomedin C on bone repair. Continuous infusion in rats. Acta Orthop Scand. 63:1992;447-450.
19. Thaller S.R., Dart A., Tesluk H. The effects of insulin-like growth factor-1 on critical-size calvarial defects in Sprague-Dawley rats. Ann Plast Surg. 31:1993;429-433.
20. Thaller S.R., Hoyt J., Tesluk H., Holmes R. Effect of insulin-like growth factor-1 on zygomatic arch bone regeneration a preliminary histological and histometric study . Ann Plast Surg. 31:1993;421-428.
21. Meinel L., Illi O., Zapf J., Malfanti M., Merkle H.P., Gander B. Stabilizing insulin-like growth factor-I in poly(D,L-lactide-co-glycolide) microspheres. J Control Rel. 70:(1-2):2001;193-202.
22. Lopaczynski W., Harris S., Nissley P. Insulin-like growth factor-I (IGF-I) dependent phosphorylation of the IGF-I receptor in MG-63 cells. Regul Pept. 48:1993;207-216.
23. Pollak M.N., Polychronakos C., Richard M. Insulinlike growth factor I a potent mitogen for human osteogenic sarcoma . J Natl Cancer Inst. 82:1990;301-305.
24. Zapf J., Hauri C., Waldvogel M., Froesch E.R. Acute metabolic effects and half-lives of intravenously administered insulinlike growth factors I and II in normal and hypophysectomized rats. J Clin Invest. 77:1986;1768-1775.
25. Chirgwin J.M., Przybyla A.E., MacDonald R.J., Rutter W.J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 18:1979;5294-5299.
26. Nemeth G.G., Heydemann A., Bolander M.E. Isolation and analysis of ribonucleic acids from skeletal tissues. Anal Biochem. 183:1989;301-304.
27. Gibson U.E., Heid C.A., Williams P.M. A novel method for real time quantitative RT-PCR. Genome Res. 6:1996;995-1001.
28. Heid C.A., Stevens J., Livak K.J., Williams P.M. Real time quantitative PCR. Genome Res. 6:1996;986-994.
29. Koseki T., Inohara N., Chen S., Carrio R., Merino J., Hottiger M.O., Nabel G.J., Nunez G. CIPER, a novel NF kappaB-activating protein containing a caspase recruitment domain with homology to herpesvirus-2 protein E10. J Biol Chem. 274:1999;9955-9961.
30. Akatsu T., Takahashi N., Udagawa N., Imamura K., Yamaguchi A., Sato K., Nagata N., Suda T. Role of prostaglandins in interleukin-1-induced bone resorption in mice in vitro. J Bone Miner Res. 6:1991;183-189.
31. de la Mata J., Uy H.L., Guise T.A., Story B., Boyce B.F., Mundy G.R., Roodman G.D. Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J Clin Invest. 95:1995;2846-2852.
32. Hernandez-Pando R., Bornstein Q.L., Aguilar Leon D., Orozco E.H., Madrigal V.K., Martinez Cordero E. Inflammatory cytokine production by immunological and foreign body multinucleated giant cells. Immunology. 100:2000;352-358.
33. Canalis E. Skeletal growth factors. Kelsey J. Osteoporosis. 1996;261-279 Academic Press, San Diego.
34. Collin-Osdoby P., Nickols G.A., Osdoby P. Bone cell function, regulation, and communication a role for nitric oxide . J Cell Biochem. 57:1995;399-408.
35. Laffargue P., Fialdes P., Frayssinet P., Rtaimate M., Hildebrand H.F., Marchandise X. Adsorption and release of insulin-like growth factor-1 on porous tricalcium phosphate implant. J Biomed Mater Res. 49:2000;415-421.
36. Bourque W.T., Gross M., Hall B.K. Expression of four growth factors during fracture repair. Int J Dev Biol. 37:1993;573-579.
37. Steinbrech D.S., Mehrara B.J., Rowe N.M., Dudziak M.E., Saadeh P.B., Gittes G.K., Longaker M.T. Gene expression of insulin-like growth factors I and II in rat membranous osteotomy healing. Ann Plast Surg. 42:1999;481-487.
38. Schneider RC. Die Knochendefektheilung unter Berücksichtigung der spontanen Regulation durch Wachstumsfaktoren und Einsatz eines synthetischen Knochenersatzes. Department of Veterinary Surgery, Musculoskeletal Research Unit. Zurich: University of Zurich; 2002.
39. Piattelli A., Scarano A., Coraggio F., Matarasso S. Early tissue reactions to polylactic acid resorbable membranes a histological and histochemical study in rabbit . Biomaterials. 19:1998;889-896.
40. Athanasiou K.A., Niederauer G.G., Agrawal C.M. Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. Biomaterials. 17:1996;93-102.
41. Takayanagi H., Kim S., Matsuo K., Suzuki H., Suzuki T., Sato K., Yokochi T., Oda H., Nakamura K., Ida N., Wagner E.F., Taniguchi T. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature. 416:2002;744-749.
42. Janssen-Heininger Y.M., Poynter M.E., Baeuerle P.A. Recent advances towards understanding redox mechanisms in the activation of nuclear factor kappaB. Free Radic Biol Med. 28:2000;1317-1327.
43. Surh Y.J., Chun K.S., Cha H.H., Han S.S., Keum Y.S., Park K.K., Lee S.S. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation . Mutat Res. 480-481:2001;243-268.